Navigation Links
Pfizer Says Nigerian Court Lacks Jurisdiction to Hear Drug Case

US drug giant Pfizer Wednesday asked a Nigerian court to strike out a lawsuit against it by a state government over a failed 1996 drug test, saying the court lacked jurisdiction to hear the case.

Authorities in Kano, Nigeria's largest state, are seeking 2.75 billion dollars from Pfizer in compensation for the victims of the drug test which took place 11 years ago.

"This court has no jurisdiction to entertain this case ... I want this court to strike out this case", Pfizer's lawyer Anthony Idigbe told the court.

Kano government's lawyer Aliyu Umar asked for more time to enable him prepare his response to Pfizer's request.

Presiding judge Sanusi Ciroma Yusuf then adjourned the hearing to July 30.

The Kano government accuses Pfizer of administering a test antibiotic called Trovan without authorisation or parental consent among children at a field hospital during an epidemic in the city of meningitis, measles and cholera.

Of the 200 children affected, 11 died while many more -- reportedly 181 -- suffered from deafness, paralysis, brain damage and blindness, according to the allegations. Pfizer denies the charges.

The Nigerian federal government filed a similar lawsuit on June 4 in Abuja for almost seven billion dollars (5.2 billion euros) in damages against the US drug firm.

But the government's case suffered an early setback on June 26 when the court rejected a request to allow it to submit "additional facts", before presiding judge Babs Kwewumi adjourned the trial to July 20.

The US Food and Drug Administration (FDA) cleared Trovan for adult use in 1997 and the drug swiftly became established as one of the most prescribed antibiotics in the US market.


'"/>




Page: 1

Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. FDA Approves Pfizer’s Anti-smoking Dru
10. Pfizer vouches safety of long-term inhaled insulin.
11. NICE Setback Rules for Pfizers Inhaled Insulin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology: